compound tirzepatide ban update Troubling Findings in Study of GLP-1 Compounders COMPOUNDED TIRZEPATIDE

Order yours online today

The pollsters reported that their findings indicate the obesity rate in the United States has decreased from a record high of nearly 40% in 2022 to 37% in 2025

Managing sleep, reducing stress where possible, and pacing your cognitive demands (not just physical ones) can all help

Sharma, Raman

For patients already meeting indications for use of a GLP-1 drug based on metabolic factors, its potential role in lowering uveitis risk could be an added consideration when selecting antihyperglycemic therapy. 1 While these possibilities are positive advancements, a commentary on the study, also published yesterday in JAMA Ophthalmology , provides some potential limitations to keep in mind when interpreting conclusions

In addition, it has been demonstrated the specific involvement of endothelial GLP-1R in contributing to the anti-hypertensive effects by controlling nitric oxide bioavailability (Richards et al., 2014